AVERAGE ANALYSTS PRICE TARGET $1.50
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
TRACON Pharmaceuticals , Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
Sign Up for our 100% Free Email Newsletter:
Text Message Alerts ---> text 'PS101' to 67076
(It's FREE, however Msg&Data rates may apply.)